MX2020005775A - Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19. - Google Patents

Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19.

Info

Publication number
MX2020005775A
MX2020005775A MX2020005775A MX2020005775A MX2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A
Authority
MX
Mexico
Prior art keywords
cardiac
covid
pirfenidone
cardiomyopathy
pharmaceutical use
Prior art date
Application number
MX2020005775A
Other languages
Spanish (es)
Inventor
García Arturo Santos
Rodríguez Ana Soledad Sandoval
Borunda Juan Socorro Armendáriz
Cuevas Jorge Gutiérrez
Original Assignee
Centro De Retina Medica Y Quirurgica S C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Retina Medica Y Quirurgica S C filed Critical Centro De Retina Medica Y Quirurgica S C
Priority to MX2020005775A priority Critical patent/MX2020005775A/en
Priority to PCT/MX2021/000019 priority patent/WO2022015141A1/en
Publication of MX2020005775A publication Critical patent/MX2020005775A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to the field of drugs for reducing cardiac fibrosis with the expression of troponin I, specifically to the pharmaceutical use that contains 5-methyl -1-phenyl -2-(1H) -pyridine (Pirfenidone) as an active ingredient alone or in combination with any other bioactive molecule for managing patients with cardiomyopathy, cardiac steatosis, and COVID-19.
MX2020005775A 2020-07-13 2020-07-13 Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19. MX2020005775A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2020005775A MX2020005775A (en) 2020-07-13 2020-07-13 Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19.
PCT/MX2021/000019 WO2022015141A1 (en) 2020-07-13 2021-06-03 Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy and/or cardiac steatosis and/or covid-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020005775A MX2020005775A (en) 2020-07-13 2020-07-13 Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19.

Publications (1)

Publication Number Publication Date
MX2020005775A true MX2020005775A (en) 2022-01-14

Family

ID=79554854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005775A MX2020005775A (en) 2020-07-13 2020-07-13 Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19.

Country Status (2)

Country Link
MX (1) MX2020005775A (en)
WO (1) WO2022015141A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (en) * 1989-02-15 1990-08-28 Yamauchi Akitomo Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion
US20190247373A1 (en) * 2016-07-14 2019-08-15 Children's Hospital Medical Center Methods for treating fibrosis
WO2018164098A1 (en) * 2017-03-06 2018-09-13 国立大学法人大阪大学 Cell population to be used as heart fiberization model, method for producing same, screening method using same, method for evaluating heart fiberization model using same, and system for evaluating heart fiberization model
CN111481547A (en) * 2020-04-16 2020-08-04 青岛海洋生物医药研究院股份有限公司 Application of pirfenidone or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/or treating novel coronavirus inflammation

Also Published As

Publication number Publication date
WO2022015141A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
RU2017127135A (en) THERAPEUTICALLY AGAINST CANCER OF CANCER
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
MX2018010788A (en) Ophthalmological composition.
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
MX2018005194A (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same.
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
MXPA05013637A (en) Gsk-3 inhibitors and uses thereof.
MX2019002265A (en) Use of pridopidine for treating functional decline.
IN2014DN08870A (en)
CR20220005A (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
EA201691008A1 (en) 7-BENZYL-4- (2-METHYLBENZIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PIRIDO [3,4-E] PYRIMIDIN-5 (1H) -OH SALTS AND APPLICATIONS
MX2015008837A (en) Stable parenteral dnj compositions.
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
MX2023004188A (en) Phospholipid compounds and uses thereof.
MX2020005775A (en) Pharmaceutical use of pirfenidone for reducing cardiac fibrosis in patients with cardiomyopathy, cardiac steatosis, and covid-19.
MX2021000094A (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis.
MX2023002482A (en) Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient.
MY160904A (en) Piperazines as antimalarial agents
PH12019501785A1 (en) Intranasal composition comprising betahistine
MX2018015707A (en) Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors.
EP1603595A4 (en) Pharmaceutical composition for treatment of drug dependence
Cayla et al. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population
MX2020014124A (en) Aptamer preparation.
MX2022012033A (en) Coronavirus infection treatment drug.
SG11201903834XA (en) Medical skin external preparation